CymaBay Following The Leaders, Pursues NASH, PBC Simultaneously
Executive Summary
Biotech thinks its PPAR delta agonist will prove much more potent than Genfit’s elafibranor from the same class and will offer a better tolerability profile than Intercept’s OCA.